Resources
7 Results (showing 1 - 7)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 3/25/2021 (updated 4/5/2024)
Recovery Housing, Medications for OUD (MOUD), and Emerging Issues
Presenters will explain recovery housing and MOUD in the context of issues emerging in rural America resulting from the pandemic and its impact on the rates of substance use disorder (SUD) and drug overdose. They will discuss the impact of the pandemic on the correctional system and state actions in response to COVID-19 as it affects those with SUD. They will also give an overview of how recovery housing can be developed, especially in rural areas.
Posted 3/25/2021 (updated 4/5/2024)
Care Coordination: Navigating Individuals With OUD Through a Treatment and Recovery Continuum
Presenters from the Western Region will describe two innovative care coordination strategies and models from the RCORP/Rural Health Opioid Program grantee perspective.
Posted 3/25/2021 (updated 4/5/2024)
State and Regional Focused Presentations: State Substance Use Prevention Systems and the National Prevention Network
Presenters will review the structure and function of state substance use prevention systems, describe the role and activities of the National Prevention Network, and highlight rural prevention initiatives.
Posted 3/28/2024 (updated 4/4/2024)
This presentation suggested RCORP grantees and the behavioral health system in general should scale up parenting classes provided to clients across the continuum.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Rapid Fire Session was held in the Independence Ballroom Salons D & E on Friday, March 6, 2020, at 9:00 AM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Capitol Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.